Newly-Funded Receptos Bets On The Safety Of Its Oral MS Drug
This article was originally published in The Pink Sheet Daily
Privately held San Diego firm is staked with $25 million in a Series A involving four VC investors.
You may also be interested in...
Which kinds of innovations make for incremental enhancements in the hands of large companies and which are meaningful enough to sustain a venture-backed start-up company? In a mature market for coronary stents dominated by large companies, start-ups developing new stents need to find the answers. Areas of innovation fall into four basic categories: improving stent safety and biocompatibility, avoiding the need for dual antiplatelet therapy, enhancing deliverability, and introducing specialty stents for complex vessels. Three companies profiled here have a plan for taking sufficient market share, reducing risk, and rewarding investors.
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
FREEDOMS clinical trial show lower levels of cancer than first Phase III trial, but Novartis goes one step further by eliminating the highest dose of its oral MS therapy and thus minimizing the side effects associated with FTY720.